论文部分内容阅读
目的:观察醒脑静注射液对急性脑梗死(ACI)核因子E2相关因子(Nrf2)、血红素氧合酶-1(HO-1)、醌氧化还原酶1(NQO1)以及临床疗效的影响。方法:2015年1月~2015年11月在我院住院ACI患者70例,随机分为对照组及治疗组各35例,2组均进行常规治疗,治疗组加用醒脑静30ml加入0.9%生理盐水注射液250ml,静脉滴注,每日1次,连用14d。比较2组治疗前以及治疗后7、14d外周血Nrf2、HO-1和NQO1水平,观察治疗前后2组ACI患者神经功能缺损量表(CNS)评分、血生化指标以及临床疗效。结果:治疗组治疗后CNS评分与对照组比较明显降低,治疗后两组Nrf2、HO-1和NQO1水平与治疗前比较均明显升高;治疗组治疗后以上指标均显著优于对照组。结论:醒脑静是对ACI有显著疗效,其作用机制可能通过上调ACI患者Nrf2、HO-1和NQO1水平,起到改善患者神经功能缺损和临床综合疗效的作用。
Objective: To observe the effects of xingnaojing injection on the expression of Nrf2, HO-1, NQO1 in patients with acute cerebral infarction (ACI) and the clinical curative effect . Methods: From January 2015 to November 2015, 70 hospitalized ACI patients in our hospital were randomly divided into control group and 35 cases in treatment group. Both groups were treated routinely. The treatment group was treated with 30ml of xingnaojing plus 0.9% Saline injection 250ml, intravenous infusion, once daily, once every 14d. The levels of Nrf2, HO-1 and NQO1 were compared between the two groups before and 7 and 14 days after treatment. The neurological deficit scale (CNS) scores, blood biochemical indexes and clinical effects were observed before and after treatment in both groups. Results: After treatment, the CNS score of the treatment group was significantly lower than that of the control group. The levels of Nrf2, HO-1 and NQO1 in both groups were significantly increased after treatment compared with those before treatment. The above indexes in the treatment group were significantly better than those in the control group. Conclusion: Xingnaojing is a significant therapeutic effect on ACI. Its mechanism may play an important role in improving neurological deficit and clinical efficacy by up-regulating the levels of Nrf2, HO-1 and NQO1 in patients with ACI.